Pharmaceutical compositions of hydrophobic camptothecin derivatives
US10980798B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jul 3, 2019 |
| Grant date | Apr 20, 2021 |
| Priority date | — |
| Expiry date | Jul 3, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/6907
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provide is a method of using a topoisomerase I inhibitor in treatment of cancer to reduce bone marrow suppression. The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition. The composition has at least one hydrophobic topoisomerase I inhibitor or a pharmaceutically acceptable salt thereof, and at least one polyethylene glycol (PEG) conjugated phospholipid, wherein the molar ratio of said PEG conjugated phospholipid to said hydrophobic topoisomerase I inhibitor or said pharmaceutically acceptable salt of said hydrophobic topoisomerase I inhibitor is about 0.45:1 to about 1.05:1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.